title: Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms.
abstract: The presence of myocardial viability is predictive of improvement in regional left ventricular (LV) function after revascularization. Studies on predicting improvement in global LV function are scarce, and the amount of viable myocardium needed for improvement in LV ejection fraction (LVEF) after revascularization is unknown. Moreover, whether the presence of viability is associated with relief of heart failure symptoms after revascularization is uncertain. Hence, the aims were to define the extent of viable myocardium needed for improvement in LVEF and to determine whether preoperative viability testing can predict improvement in heart failure symptoms.
  
  
  METHODS
  Patients (n = 47) with ischemic cardiomyopathy (mean LVEF +/- SD, 30% +/- 6%) undergoing surgical revascularization were studied with 18F-FDG SPECT to assess viability. Regional and global function were measured before and 3-6 mo after revascularization. Heart failure symptoms were graded according to the New York Heart Association (NYHA) criteria, before and 3-6 mo after revascularization.
  
  
  RESULTS
  The number of viable segments per patient was directly related to the improvement in LVEF after revascularization (r = 0.79, P < 0.01). Receiver operating characteristic curve analysis revealed that the cutoff level of four viable segments (representing 31% of the left ventricle) yielded the highest sensitivity and specificity (86% and 92%, respectively) for predicting improvement in LVEF. Furthermore, the presence of four or more viable segments predicted improvement in heart failure symptoms after revascularization, with positive and negative predictive values of 76% and 71%, respectively.
  
  
  CONCLUSIONS
  The presence of substantial viability (four or more viable segments, 31% of the left ventricle) on FDG SPECT is predictive of improvement in LVEF and heart failure symptoms postoperatively.
authors.affiliation: Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: J J
authors.initials: JJ
authors.lastname: Bax
authors.forename: F C
authors.initials: FC
authors.lastname: Visser
authors.forename: D
authors.initials: D
authors.lastname: Poldermans
authors.forename: A
authors.initials: A
authors.lastname: Elhendy
authors.forename: J H
authors.initials: JH
authors.lastname: Cornel
authors.forename: E
authors.initials: E
authors.lastname: Boersma
authors.forename: R
authors.initials: R
authors.lastname: Valkema
authors.forename: A
authors.initials: A
authors.lastname: Van Lingen
authors.forename: P M
authors.initials: PM
authors.lastname: Fioretti
authors.forename: C A
authors.initials: CA
authors.lastname: Visser
mesh_terms: D002311:Cardiomyopathy, Dilated / Q000000981:diagnostic imaging* / Q000503:physiopathology / Q000601:surgery*; D016022:Case-Control Studies; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization; D017682:Myocardial Stunning / Q000000981:diagnostic imaging*; D011237:Predictive Value of Tests; D012372:ROC Curve; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D013318:Stroke Volume / Q000502:physiology*; D015899:Tomography, Emission-Computed, Single-Photon; D016277:Ventricular Function, Left / Q000502:physiology
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18